Mather, 772 patient famotidine prophylaxis PSM study: 61% lower mortality [p=0.004] and 50% lower combined mortality/intubation [p=0.003] https://c19p.org/mather
copied to clipboard
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19
et al., American Journal of Gastroenterology, doi:10.14309/ajg.0000000000000832
PSM retrospective 878 hospitalized patients in the USA, 83 with existing famotidine use, showing significantly lower mortality with treatment.
|
risk of death, 61.4% lower, HR 0.39, p = 0.004, treatment 83, control 689, propensity score matching, Cox proportional hazards.
|
|
risk of death/intubation, 50.5% lower, HR 0.49, p = 0.003, treatment 83, control 689, propensity score matching, Cox proportional hazards.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Mather et al., 8/26/2020, retrospective, USA, North America, peer-reviewed, 3 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.